Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis

Cellular Immunology

Volumn 293, Issue 2, 2015, Pages 113-121

  Gharibi, Tohid ^a   Ahmadi, Majid ^a   Seyfizadeh, Narges ^a   Jadidi Niaragh, Farhad ^b   Yousefi, Mehdi ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Immunomodulation; Mesenchymal stem cells; Multiple sclerosis

Indexed keywords

ANGIOGENESIS; APOPTOSIS; B LYMPHOCYTE; CELL INFILTRATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMYELINATION; DENDRITIC CELL; DISEASE COURSE; EX VIVO STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REMYELINIZATION; REVIEW; T LYMPHOCYTE; UPREGULATION; WHITE MATTER; ANIMAL; DISEASE MODEL; IMMUNOLOGY; MESENCHYMAL STROMA CELL; MOUSE; STANDARDS;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MULTIPLE SCLEROSIS;

EID: 84921044549     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.01.002     Document Type: Review

References (162)

1. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372(9648):1502-1517. (PubMed PMID: 18970977. Epub 2008/10/31. eng).
2. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343(13):938-952. (PubMed PMID: 11006371. Epub 2000/09/28. eng).
3. Duquette P., Pleines J., Girard M., Charest L., Senecal-Quevillon M., Masse C. The increased susceptibility of women to multiple sclerosis. Can. J. Neurol. Sci. 1992, 19(4):466-471.
4. Praksova P., Stourac P., Bednarik J., Vlckova E., Mikulkova Z., Michalek J. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. J. Neurol. Sci. 2012, 319(1):18-23.
5. Kornek B., Lassmann H. Neuropathology of multiple sclerosis-new concepts. Brain Res. Bull. 2003, 61(3):321-326.
6. Monald W.I., Sears T.A. The effects of experimental demyelination on conduction in the central nervous system. Brain 1970, 93(3):583-598. [PubMed PMID: 4319185. Epub 1970/01/01. eng].
7. Rodriguez M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. Brain Pathol. 2007, 17(2):219-229. (PubMed PMID: 17388953. Epub 2007/03/29. eng).
8. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354(9):942-955. (PubMed PMID: 16510748. Epub 2006/03/03. eng).
9. Peterson L.K., Fujinami R.S. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 2007, 184(1):37-44.
10. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338(5):278-285. (PubMed PMID: 9445407. Epub 1998/01/29. eng).
11. Arnold D.L., Narayanan S., Antel S. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. J. Neurol. 2013, 260(7):1901-1906. (PubMed PMID: 23589190. Pubmed Central PMCID: Pmc3705142. Epub 2013/04/17. eng).
12. Jadidi-Niaragh F., Mirshafiey A. Therapeutic approach to multiple sclerosis by novel oral drugs. Recent Pat. Inflamm. Allergy Drug Discov. 2011, 5(1):66-80.
13. Confavreux C., Li D.K., Freedman M.S., Truffinet P., Benzerdjeb H., Wang D., et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5years. Mult. Scler. J. 2012, 18(9):1278-1289.
14. Zivadinov R., Dwyer M., Hussein S., Carl E., Kennedy C., Andrews M., et al. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis. Mult. Scler. J. 2012, 18(8):1125-1134.
15. Chanvillard C., Millward J.M., Lozano M., Hamann I., Paul F., Zipp F., et al. Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis. PLoS One 2012, 7(6):e39625.
16. Karussis D., Grigoriadis S., Polyzoidou E., Grigoriadis N., Slavin S., Abramsky O. Neuroprotection in multiple sclerosis. Clin. Neurol. Neurosurg. 2006, 108(3):250-254.
17. Steinman L. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2001, 2(9):762-763.
18. Yi T., Song S.U. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch. Pharm. Res. 2012, 35(2):213-221. (PubMed PMID: 22370776. Epub 2012/03/01. eng).
19. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110(10):3499-3506.
20. Bai L., Lennon D.P., Eaton V., Maier K., Caplan A.I., Miller S.D., et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009, 57(11):1192-1203.
21. Constantin G., Marconi S., Rossi B., Angiari S., Calderan L., Anghileri E., et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009, 27(10):2624-2635.
22. Gerdoni E., Gallo B., Casazza S., Musio S., Bonanni I., Pedemonte E., et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann. Neurol. 2007, 61(3):219-227.
23. Grigoriadis N., Lourbopoulos A., Lagoudaki R., Frischer J.-M., Polyzoidou E., Touloumi O., et al. Variable behavior and complications of autologous bone marrow mesenchymal stem cells transplanted in experimental autoimmune encephalomyelitis. Exp. Neurol. 2011, 230(1):78-89.
24. Karussis D., Kassis I., Kurkalli B.G., Slavin S. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J. Neurol. Sci. 2008, 265(1-2):131-135. (PubMed PMID: 17610906. Epub 2007/07/06. eng).
25. Kassis I., Grigoriadis N., Gowda-Kurkalli B., Mizrachi-Kol R., Ben-Hur T., Slavin S., et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch. Neurol. 2008, 65(6):753-761.
26. Lu Z., Hu X., Zhu C., Wang D., Zheng X., Liu Q. Overexpression of CNTF in Mesenchymal Stem Cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice. J. Neuroimmunol. 2009, 206(1):58-69.
27. Rafei M., Birman E., Forner K., Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol. Ther. 2009, 17(10):1799-1803.
28. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106(5):1755-1761.
29. Auletta J.J., Bartholomew A.M., Maziarz R.T., Deans R.J., Miller R.H., Lazarus H.M., et al. The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis. Immunotherapy 2012, 4(5):529-547.
30. Friedenstein A.J., Chailakhyan R.K., Latsinik N.V., Panasyuk A.F., Keiliss-Borok I.V. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974, 17(4):331-340. (PubMed PMID: 4150881. Epub 1974/04/01. eng).
31. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276(5309):71-74. (PubMed PMID: 9082988. Epub 1997/04/04. eng).
32. Caplan A.I. Mesenchymal stem cells. J. Orthop. Res. 1991, 9(5):641-650. (PubMed PMID: 1870029. Epub 1991/09/01. eng).
33. Fibbe W.E. Mesenchymal stem cells. A potential source for skeletal repair. Ann. Rheum. Dis. 2002, 61(Suppl. 2):ii29-ii31. (PubMed PMID: 12379617. Pubmed Central PMCID: Pmc1766715. Epub 2002/10/16. eng).
34. Pittenger M.F., Martin B.J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ. Res. 2004, 95(1):9-20.
35. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8(4):315-317. (PubMed PMID: 16923606. Epub 2006/08/23. eng).
36. Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int. Rev. Neurobiol. 2007, 79:43-72. (PubMed PMID: 17531837. Epub 2007/05/29. eng).
37. Hedegaard C.J., Krakauer M., Bendtzen K., Lund H., Sellebjerg F., Nielsen C.H. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 2008, 125(2):161-169. (PubMed PMID: 18397264. Pubmed Central PMCID: Pmc2561132. Epub 2008/04/10. eng).
38. Pettinelli C., McFarlin D. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2-T lymphocytes. J. Immunol. 1981, 127(4):1420-1423.
39. Durelli L., Conti L., Clerico M., Boselli D., Contessa G., Ripellino P., et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann. Neurol. 2009, 65(5):499-509. (PubMed PMID: 19475668. Epub 2009/05/29. eng).
40. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172(1):146-155.
41. Jadidi-Niaragh F., Mirshafiey A. The deviated balance between regulatory T cell and Th17 in autoimmunity. Immunopharmacol. Immunotoxicol. 2012, 34(5):727-739.
42. Jadidi-Niaragh F., Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand. J. Immunol. 2011, 74(1):1-13.
43. Friese M.A., Fugger L. Pathogenic CD8+ T cells in multiple sclerosis. Ann. Neurol. 2009, 66(2):132-141.
44. Weiss H.A., Millward J.M., Owens T. CD8+ T cells in inflammatory demyelinating disease. J. Neuroimmunol. 2007, 191(1):79-85.
45. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99(10):3838-3843.
46. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75(3):389-397.
47. Bocelli-Tyndall C., Bracci L., Schaeren S., Feder-Mengus C., Barbero A., Tyndall A., et al. Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15. Ann. Rheum. Dis. 2009, 68(8):1352-1359.
48. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105(4):1815-1822.
49. Ghannam S., Pène J., Torcy-Moquet G., Jorgensen C., Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 2010, 185(1):302-312.
50. Mohammadzadeh A., Pourfathollah A.A., Shahrokhi S., Hashemi S.M., Moradi S.L.A., Soleimani M. Immunomodulatory effects of adipose-derived mesenchymal stem cells on the gene expression of major transcription factors of T cell subsets. Int. Immunopharmacol. 2014, 20(2):316-321.
51. Darlington P.J., Boivin M.N., Renoux C., François M., Galipeau J., Freedman M.S., et al. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: implication for multiple sclerosis. Ann. Neurol. 2010, 68(4):540-545.
52. Guo Z., Zheng C., Chen Z., Gu D., Du W., Ge J., et al. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. Eur. J. Immunol. 2009, 39(10):2840-2849.
53. Ma S., Zhong D., Chen H., Zheng Y., Sun Y., Luo J., et al. The immunomodulatory effect of bone marrow stromal cells (BMSCs) on interleukin (IL)-23/IL-17-mediated ischemic stroke in mice. J. Neuroimmunol. 2013, 257(1):28-35.
54. Liu P., Xuan X., Zhu J., Guan S., DU Y, Li Q Therapeutic effect of allogenic bone marrow mesenchymal stem cell transplantation on EAE mouse. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2013, 29(8):798-801.
55. Oh J.Y., Kim T.W., Jeong H.J., Lee H.J., Ryu J.S., Wee W.R., et al. Intraperitoneal infusion of mesenchymal stem/stromal cells prevents experimental autoimmune uveitis in mice. Mediators Inflamm. 2014, 2014.
56. Grote K., Petri M., Liu C., Jehn P., Spalthoff S., Kokemüller H., et al. Toll-like receptor 2/6-dependent stimulation of mesenchymal stem cells promotes angiogenesis by paracrine factors. Eur. Cell Mater. 2013, 26:66-79.
57. Conforti A., Scarsella M., Starc N., Giorda E., Biagini S., Proia A., et al. Microvescicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro. Stem Cells Dev. 2014.
58. Maccario R., Podestà M., Moretta A., Cometa A., Comoli P., Montagna D., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005, 90(4):516-525.
59. Angoulvant D., Clerc A., Benchalal S., Galambrun C., Farre A., Bertrand Y., et al. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 2004, 41(3):469-476.
60. Prigione I., Benvenuto F., Bocca P., Battistini L., Uccelli A., Pistoia V. Reciprocal interactions between human mesenchymal stem cells and γδ T cells or invariant natural killer T cells. Stem Cells 2009, 27(3):693-702.
61. Augello A., Tasso R., Negrini S.M., Amateis A., Indiveri F., Cancedda R., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 2005, 35(5):1482-1490.
62. Chabannes D., Hill M., Merieau E., Rossignol J., Brion R., Soulillou J.P., et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007, 110(10):3691-3694.
63. English K., Ryan J., Tobin L., Murphy M., Barry F., Mahon B. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+ CD25Highforkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 2009, 156(1):149-160.
64. Gieseke F., Böhringer J., Bussolari R., Dominici M., Handgretinger R., Müller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010, 116(19):3770-3779.
65. Gieseke F., Schütt B., Viebahn S., Koscielniak E., Friedrich W., Handgretinger R., et al. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNγR1 signaling and IDO expression. Blood 2007, 110(6):2197-2200.
66. Groh M.E., Maitra B., Szekely E., Koç O.N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol. 2005, 33(8):928-934.
67. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., et al. Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006, 24(2):386-398.
68. Liotta F., Angeli R., Cosmi L., Fili L., Manuelli C., Frosali F., et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing notch signaling. Stem Cells 2008, 26(1):279-289.
69. Nasef A., Mathieu N., Chapel A., Frick J., François S., Mazurier C., et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007, 84(2):231-237.
70. Nasef A., Mazurier C., Bouchet S., François S., Chapel A., Thierry D., et al. Leukemia inhibitory factor: role in human mesenchymal stem cells mediated immunosuppression. Cell. Immunol. 2008, 253(1):16-22.
71. Rasmusson I., Ringdén O., Sundberg B., Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp. Cell Res. 2005, 305(1):33-41.
72. Ryan J., Barry F., Murphy J., Mahon B. Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 2007, 149(2):353-363.
73. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26(1):212-222.
74. Meisel R., Zibert A., Laryea M., Göbel U., Däubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103(12):4619-4621.
75. Chan J.L., Tang K.C., Patel A.P., Bonilla L.M., Pierobon N., Ponzio N.M., et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-γ. Blood 2006, 107(12):4817-4824.
76. François M., Romieu-Mourez R., Stock-Martineau S., Boivin M.-N., Bramson J.L., Galipeau J. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 2009, 114(13):2632-2638.
77. Karni A., Abraham M., Monsonego A., Cai G., Freeman G.J., Hafler D., et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 2006, 177(6):4196-4202.
78. Menges M., Rößner S., Voigtländer C., Schindler H., Kukutsch N.A., Bogdan C., et al. Repetitive injections of dendritic cells matured with tumor necrosis factor α induce antigen-specific protection of mice from autoimmunity. J. Exp. Med. 2002, 195(1):15-22.
79. Jiang X.-X., Zhang Y., Liu B., Zhang S.-X., Wu Y., Yu X.-D., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105(10):4120-4126.
80. Spaggiari G.M., Abdelrazik H., Becchetti F., Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009, 113(26):6576-6583.
81. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005, 105(5):2214-2219.
82. Opitz C.A., Litzenburger U.M., Lutz C., Lanz T.V., Tritschler I., Köppel A., et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2, 3-dioxygenase-1 via interferon-β and protein kinase R. Stem Cells 2009, 27(4):909-919.
83. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010, 5(4):e10088.
84. Hwang S.H., Cho H.K., Park S.H., Lee W., Lee H.J., Lee D.C., et al. Toll like receptor 3 & 4 responses of human turbinate derived mesenchymal stem cells: stimulation by double stranded RNA and lipopolysaccharide. PLoS One 2014, 9(7):e101558.
85. Dumitru C.A., Hemeda H., Jakob M., Lang S., Brandau S. Stimulation of mesenchymal stromal cells (MSCs) via TLR3 reveals a novel mechanism of autocrine priming. FASEB J. 2014, (fj. 14-250159).
86. van den Akker F., de Jager S., Sluijter J. Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors. Mediators Inflamm. 2013, 2013.
87. Zhao X., Liu D., Gong W., Zhao G., Liu L., Yang L., et al. The toll-like receptor 3 ligand, poly (I: C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143. Stem Cells 2014, 32(2):521-533.
88. Poggi A., Prevosto C., Massaro A.-M., Negrini S., Urbani S., Pierri I., et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J. Immunol. 2005, 175(10):6352-6360.
89. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006, 24(1):74-85.
90. LeMaoult J., Zafaranloo K., Le Danff C., Carosella E.D. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J. 2005, 19(6):662-664.
91. Breij E.C., Brink B.P., Veerhuis R., Van den Berg C., Vloet R., Yan R., et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 2008, 63(1):16-25.
92. Vyshkina T., Kalman B. Autoantibodies and neurodegeneration in multiple sclerosis. Lab. Invest. 2008, 88(8):796-807.
93. Glennie S., Soeiro I., Dyson P.J., Lam E.W.-F., Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105(7):2821-2827.
94. Gordon D., Pavlovska G., Glover C.P., Uney J.B., Wraith D., Scolding N.J. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci. Lett. 2008, 448(1):71-73.
95. Schäfer R., Ayturan M., Bantleon R., Kehlbach R., Siegel G., Pintaske J., et al. The use of clinically approved small particles of iron oxide (SPIO) for labeling of mesenchymal stem cells aggravates clinical symptoms in experimental autoimmune encephalomyelitis and influences their in vivo distribution. Cell Transplant. 2008, 17(8):923-941.
96. Kemp K., Gordon D., Wraith D., Mallam E., Hartfield E., Uney J., et al. Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells. Neuropathol. Appl. Neurobiol. 2011, 37(2):166-178.
97. Rafei M., Birman E., Forner K., Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol. Ther. 2009, 17(10):1799-1803. (PubMed PMID: 19602999. Pubmed Central PMCID: Pmc2835011. Epub 2009/07/16. eng).
98. Fisher-Shoval Y., Barhum Y., Sadan O., Yust-Katz S., Ben-Zur T., Lev N., et al. Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS. J. Mol. Neurosci. 2012, 48(1):176-184.
99. Harris V.K., Yan Q.J., Vyshkina T., Sahabi S., Liu X., Sadiq S.A. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J. Neurol. Sci. 2012, 313(1):167-177.
100. Harris V.K., Faroqui R., Vyshkina T., Sadiq S.A. Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis. Stem Cells Transl. Med. 2012, 1(7):536-547.
101. Liu R., Zhang Z., Lu Z., Borlongan C., Pan J., Chen J., et al. Human umbilical cord stem cells ameliorate experimental autoimmune encephalomyelitis by regulating immunoinflammation and remyelination. Stem Cells Dev. 2012, 22(7):1053-1062.
102. Tafreshi A.P., Payne N., Sun G., Sylvain A., Schulze K., Bernard C. Inactive GSK3β is disturbed in the spinal cord during experimental autoimmune encephalomyelitis, but rescued by stem cell therapy. Neuroscience 2014.
103. Yousefi F., Ebtekar M., Soleimani M., Soudi S., Hashemi S.M. Comparison of in vivo immunomodulatory effects of intravenous and intraperitoneal administration of adipose-tissue mesenchymal stem cells in experimental autoimmune encephalomyelitis (EAE). Int. Immunopharmacol. 2013, 17(3):608-616.
104. Wang X., Kimbrel E.A., Ijichi K., Paul D., Lazorchak A.S., Chu J., et al. Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of Multiple Sclerosis. Stem Cell Rep. 2014.
105. Zhang Y.-J., Zhang W., Lin C.-G., Ding Y., Huang S.-F., Wu J.-L., et al. Neurotrophin-3 gene modified mesenchymal stem cells promote remyelination and functional recovery in the demyelinated spinal cord of rats. J. Neurol. Sci. 2012, 313(1):64-74.
106. Cobo M., Anderson P., Benabdellah K., Toscano M.G., Muñoz P., García-Pérez A., et al. Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis. Cell Transplant. 2013, 22(5):839-854.
107. Payne N.L., Sun G., McDonald C., Moussa L., Emerson-Webber A., Loisel-Meyer S., et al. Human adipose-derived mesenchymal stem cells engineered to secrete IL-10 inhibit APC function and limit CNS autoimmunity. Brain Behav. Immun. 2013, 30:103-114.
108. Ryu C.H., Park K.Y., Hou Y., Jeong C.H., Kim S.M., Jeun S.-S. Gene therapy of multiple sclerosis using interferon β-secreting human bone marrow mesenchymal stem cells. BioMed Res. Int. 2013, 2013.
109. Hou Y., Ryu C.H., Jun J., Kim S.M., Jeong C.H., Jeun S.-S. Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2014.
110. Fransson M., Piras E., Wang H., Burman J., Duprez I., Harris R.A., et al. Intranasal delivery of CNS-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis. Immunology 2014.
111. Ragerdi K.I., Hedayatpour A., Pasbakhsh P., Kafami L., Atlasi N., Pirhajati M.V., et al. 17β-Estradiol enhances the efficacy of adipose-derived mesenchymal stem cells on remyelination in mouse model of multiple sclerosis. Acta Med. Iran. 2011, 50(12):789-797.
112. Hedayatpour A., Ragerdi I., Pasbakhsh P., Kafami L., Atlasi N., Mahabadi V.P., et al. Promotion of remyelination by adipose mesenchymal stem cell transplantation in a cuprizone model of multiple sclerosis. Cell J. (Yakhteh) 2013, 15(2):142.
113. Nessler J., Bénardais K., Gudi V., Hoffmann A., Tejedor L.S., Janßen S., et al. Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination. PLoS One 2013, 8(7):e69795.
114. Hou Y., Ryu C.H., Park K.Y., Kim S.M., Jeong C.H., Jeun S.-S. Effective combination of human bone marrow mesenchymal stem cells and minocycline in experimental autoimmune encephalomyelitis mice. Stem Cell Res. Ther. 2013, 4(4):77.
115. Dang S., Xu H., Xu C., Cai W., Li Q., Zhang Y., et al. Autophagy regulates the therapeutic potential of mesenchymal stem cells in experimental autoimmune encephalomyelitis. Autophagy 2014, 10(7):62-71.
116. Zepp J., Wu L., Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol. 2011, 32(5):232-239.
117. English K., Barry F.P., Field-Corbett C.P., Mahon B.P. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett. 2007, 110(2):91-100. (PubMed PMID: 17507101. Epub 2007/05/18. eng).
118. Nemeth K., Leelahavanichkul A., Yuen P.S., Mayer B., Parmelee A., Doi K., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E[2]-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 2009, 15(1):42-49. (PubMed PMID: 19098906. Pubmed Central PMCID: Pmc2706487. Epub 2008/12/23. eng).
119. Napoli I., Neumann H. Protective effects of microglia in multiple sclerosis. Exp. Neurol. 2010, 225(1):24-28.
120. Auletta J.J., Cooke K.R., Solchaga L.A., Deans R.J., van't Hof W. Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions. Biol. Blood Marrow Transplant. 2010, 16(7):891-906.
121. Bai L., Lennon D.P., Caplan A.I., DeChant A., Hecker J., Kranso J., et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat. Neurosci. 2012, 15(6):862-870.
122. Buckner J.H. Mechanisms of impaired regulation by CD4+ CD25+ FOXP3+ regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 2010, 10(12):849-859.
123. Schneider A., Long S.A., Kita M., Buckner J.H. Persistence of FOXP3 expression is impaired in RR-MS Tregs. J. Immunol. 2009, 182(99):3.
124. Jadidi-Niaragh F., Mirshafiey A. Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis. Immunopharmacol. Immunotoxicol. 2011, 33(3):545-567.
125. Shi M., Liu Z.W., Wang F.S. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin. Exp. Immunol. 2011, 164(1):1-8.
126. Bonab M. FOXP3 gene expression in multiple sclerosis patients pre-and post mesenchymal stem cell therapy. Iran. J. Allergy Asthma Immunol. 2011, 10(3).
127. Zhu J., Zhang J., Li Q., Du Y., Qiao B., Hu X. Transplanting of mesenchymal stem cells may affect proliferation and function of CD4 (+) T cells in experimental autoimmune encephalomyelitis. Exp. Clin. Transpl. 2012, 10(5):492-500.
128. Guo Y., Chan K.-H., Lai W.-H., Siu C.-W., Kwan S.-C., Tse H.-F., et al. Human mesenchymal stem cells upregulate CD1dhighCD5+ regulatory B cells in experimental autoimmune encephalomyelitis. NeuroImmunoModulation 2013, 20(5):294-303.
129. Jaramillo-Merchán J., Jones J., Ivorra J., Pastor D., Viso-León M., Armengól J., et al. Mesenchymal stromal-cell transplants induce oligodendrocyte progenitor migration and remyelination in a chronic demyelination model. Cell Death Dis. 2013, 4(8):e779.
130. Sun H., Bénardais K., Stanslowsky N., Thau-Habermann N., Hensel N., Huang D., et al. Therapeutic potential of mesenchymal stromal cells and MSC conditioned medium in amyotrophic lateral sclerosis (ALS)-in vitro evidence from primary motor neuron cultures, NSC-34 cells, astrocytes and microglia. PLoS One 2013, 8(9):e72926.
131. Fu X.M., Liu S.J., Dan Q.Q., Wang Y.P., Lin N., Lv L.Y., et al. Combined bone mesenchymal stem cells and olfactory ensheathing cells transplantation promote neural repair associated with CNTF expression in traumatic brain injured rats. Cell Transplant. 2014.
132. Lanza C., Morando S., Voci A., Canesi L., Principato M.C., Serpero L.D., et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J. Neurochem. 2009, 110(5):1674-1684.
133. Kemp K., Hares K., Mallam E., Heesom K.J., Scolding N., Wilkins A. Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival. J. Neurochem. 2010, 114(6):1569-1580.
134. Kemp K., Gray E., Mallam E., Scolding N., Wilkins A. Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human mesenchymal stem cells. Stem Cell Rev. Rep. 2010, 6(4):548-559.
135. Voulgari-Kokota A., Fairless R., Karamita M., Kyrargyri V., Tseveleki V., Evangelidou M., et al. Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function. Exp. Neurol. 2012, 236(1):161-170.
136. Koning J.J., Kooij G., de Vries H.E., Nolte M.A., Mebius R.E. Mesenchymal stem cells are mobilized from the bone marrow during inflammation. Front Immunol. 2013, 4:49. (PubMed PMID: 23459632. Pubmed Central PMCID: Pmc3586765. Epub 2013/03/06. eng).
137. Devine S.M., Cobbs C., Jennings M., Bartholomew A., Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003, 101(8):2999-3001.
138. Kopen G.C., Prockop D.J., Phinney D.G. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc. Natl. Acad. Sci. 1999, 96(19):10711-10716.
139. Barhum Y., Gai-Castro S., Bahat-Stromza M., Barzilay R., Melamed E., Offen D. Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis. J. Mol. Neurosci. 2010, 41(1):129-137.
140. Bonab M.M., Yazdanbakhsh S., Lotfi J., Alimoghaddom K., Talebian F., Hooshmand F., et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran. J. Immunol. 2007, 4(1):50-57.
141. Zhong Z., Patel A.N., Ichim T.E., Riordan N.H., Wang H., Min W.-P., et al. Feasibility investigation of allogeneic endometrial regenerative cells. J. Transl. Med. 2009, 7(15):29-37.
142. Liang J., Zhang H., Hua B., Wang H., Wang J., Han Z., et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult. Scler. 2009, 15(5):644-646.
143. Yamout B., Hourani R., Salti H., Barada W., El-Hajj T., Al-Kutoubi A., et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J. Neuroimmunol. 2010, 227(1):185-189.
144. Karussis D., Karageorgiou C., Vaknin-Dembinsky A., Gowda-Kurkalli B., Gomori J.M., Kassis I., et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. Neurol. 2010, 67(10):1187-1194.
145. Connick P., Kolappan M., Patani R., Scott M.A., Crawley C., He X.-L., et al. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials 2011, 12(1):62.
146. Hammadi A.M.A., Marino A., Farhan S. Clinical outcome of 50 progressive multiple sclerosis patients treated with cellular therapy in Iraq. Int. J. Stem Cells 2011, 4(2):113.
147. Connick P., Kolappan M., Crawley C., Webber D.J., Patani R., Michell A.W., et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012, 11(2):150-156.
148. Odinak M., Bisaga G., Novitskiĭ A., Tyrenko V., Fominykh M., Bilibina A., et al. Transplantation of mesenchymal stem cells in multiple sclerosis. Zh. Nevrol. Psikhiatr. Im. S S Korsakova 2010, 111(2 Pt 2):72-76.
149. Mohyeddin Bonab M., Ali Sahraian M., Aghsaie A., Ahmadi Karvigh S., Massoud Hosseinian S., Nikbin B., et al. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study. Curr. Stem Cell Res. Ther. 2012, 7(6):407-414.
150. Mohajeri M., Farazmand A., Bonab M.M., Nikbin B., Minagar A. FOXP3 gene expression in multiple sclerosis patients pre-and post mesenchymal stem cell therapy. Iran. J. Allergy Asthma Immunol. 2011, 10(3):155-161.
151. Mohyeddin Bonab M., Mohajeri M., Sahraian M.A., Yazdanifar M., Aghsaie A., Farazmand A., et al. Evaluation of cytokines in multiple sclerosis patients treated with mesenchymal stem cells. Arch. Med. Res. 2013, 44(4):266-272.
152. Hou Z.-l., Liu Y., Mao X.-H., Wei C.-y., Meng M.-y., Liu Y., et al. Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis. Cell Adhes. Migr. 2013, 7(5):404.
153. Joyce N., Annett G., Wirthlin L., Olson S., Bauer G., Nolta J.A. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen. Med. 2010, 5(6):933-946.
154. Ng T.K., Fortino V.R., Pelaez D., Cheung H.S. Progress of mesenchymal stem cell therapy for neural and retinal diseases. World J. Stem Cells 2014, 6(2):111.
155. García-Castro J., Trigueros C., Madrenas J., Pérez-Simón J., Rodriguez R., Menendez P. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J. Cell Mol. Med. 2008, 12(6b):2552-2565.
156. William T.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75(3):389-397.
157. Chamberlain G., Fox J., Ashton B., Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007, 25(11):2739-2749.
158. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 2003, 31(10):890-896.
159. Polchert D., Sobinsky J., Douglas G., Kidd M., Moadsiri A., Reina E., et al. IFN-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 2008, 38(6):1745-1755.
160. Mallam E., Kemp K., Wilkins A., Rice C., Scolding N. Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Mult. Scler. 2010.
161. Zafranskaya M., Nizheharodava D., Yurkevich M., Ivanchik G., Demidchik Y., Kozhukh H., et al. PGE2 contributes to in vitro MSC-mediated inhibition of non-specific and antigen-specific T cell proliferation in MS patients. Scand. J. Immunol. 2013, 78(5):455-462.
162. de Oliveira G., de Lima K., Colombini A.M., Pinheiro D.G., Panepucci R.A., Palma P., et al. Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts. Cell Transplant. 2013.